2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 159

VA Musculoskeletal “Master Educator” Faculty Development Program for Health Professions Educators: Follow-Up on Changes in Educational Duties and Perceptions of Program Content

Education Poster

9:00AM-11:00AM: Abstract Number: 636

Validation and Transcultural Adaptation of the Spanish Version of Brief Index of Lupus Damage (BILD) Questionnaire

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 443

Validation of a Risk Perception Questionnaire Developed for Patients with Rheumatoid Arthritis

Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes

9:00AM-11:00AM: Abstract Number: 415

Validation of a Satisfaction Measure for Use in Total Joint Replacement Clinical Trials

Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes

9:00AM-11:00AM: Abstract Number: 189

Validation of Claims-based Algorithms to Identify Interstitial Lung Disease in Patients with Rheumatoid Arthritis

Epidemiology & Public Health Poster I: RA

9:00AM-11:00AM: Abstract Number: 44

Validation of New Genes Identified in a Molecular Bayesian Network of Rheumatoid Arthritis Synovitis

RA – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 490

Validation of Risk Scores for Predicting Progression in Individuals “At Risk of Rheumatoid Arthritis”

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 741

Vascular Damage Is Less Present in an Early Inception Cohort in Takayasu’s Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Takayasu's Arteritis & Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 456

Vitamin D Is Not Associated with Treatment Responses in Patients with Newly Diagnosed Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 771

Von Willebrand Factor Is Localized in the Extravascular Tissue of Patients with Juvenile Scleroderma

Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

9:00AM-11:00AM: Abstract Number: 733

Vonoprazan, a Novel Potassium-competitive Acid Blocker, for Treatment of Proton Pump Inhibitor-resistant Reflux Esophagitis in Patients with Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 157

We Can Do Better: Evaluating Inpatient Pediatric Rheumatology Inpatient/Consult Service Performance

Education Poster

9:00AM-11:00AM: Abstract Number: 445

What Is the Effect of Statins on the Risk of Rheumatoid Arthritis? Results of a Systematic Review and Meta-Analysis

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 595

What Is the Impact of Discrepancy Between Central and Local Readers in Evaluation of MRI Scans on the Classification of Axial Spondyloarthritis? Data from the ASAS Classification Cohort Study

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 590

What Is the Impact of MRI on the Performance of the ASAS Classification Criteria in Patients Presenting with Undiagnosed Back Pain?

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].